The chairman of the Chinese Center for Infectious Diseases admitted that the government intends to try and mix various vaccines made in China in an attempt to increase their effectiveness, which turned out to be low
Use of the Chinese vaccine Indonesia // Photo: Reuters
The chairman of the Center for Infectious Disease Control, Gao Fu, admitted today (Sunday) that the effectiveness of the vaccines developed in his country against coronary heart disease is low and the country is considering giving more than one vaccine and mixing the various doses in order to try and achieve greater protection against the virus.
Gao, in a confession that is considered rare in the Chinese public sector, said studies indicated that the effectiveness of vaccines made in his country was "not very great" during a special conference in the southwestern city of Chengdu.
This comes after the Chinese government has already distributed hundreds of millions of vaccine doses of its products, mostly from Sinovak, around the world, and even tried to sow doubts about the effectiveness of vaccines from foreign companies such as Pfizer and Biontech.
Whereas in the past the Chinese authorities have questioned the use of the "messenger RNA" method used by Pfizer Modern vaccine, now Gao said that "we are officially considering the use of different methods of vaccination in parallel to increase the effectiveness of the immunization process".
Chinese MRNA vaccine is currently in clinical trials but more information about the process is not available to the public.
The corona crisis, which began in Wuhan city of China, was the first global crisis in which the Chinese pharmaceutical industry tried to play an important role as a world leader, and the statement by the chairman of the Center for Infectious Disease Control is a severe blow to the industry.
Sinovak and Sinopharm, two state-owned companies, have taken over most of the vaccine production in China.
Studies conducted in Brazil have shown that the vaccines of both companies are effective in just over 50 percent of cases.
To date, China has not approved the use of any foreign-made vaccine in its territory.
